WINSTON-SALEM, N.C., Feb. 12 /PRNewswire-FirstCall/ -- Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it will conduct a conference call and audio webcast at 5:00 p.m. ET on Thursday, February 22, 2007 following the after-market release of its financial results for the fourth quarter and year ended December 31, 2006. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call, during which they will discuss Targacept’s financial results and provide an update on the company’s product development programs and business activities.
A live webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept’s website for at least two weeks following the call.
The conference call may be accessed by dialing 866-713-8307 for domestic participants and 617-597-5307 for international callers (reference passcode 33628065). A replay of the conference call may be accessed through March 8, 2007 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 31233017).
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system activity to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer’s disease and cognitive deficits in schizophrenia, pain and depression and anxiety disorders, and multiple preclinical programs. Targacept is located in Winston-Salem, North Carolina.
Targacept, Inc.
CONTACT: Alan Musso, VP and CFO of Targacept, +1-336-480-2186,alan.musso@targacept.com; or Michelle Linn of Linnden Communications,+1-508-419-1555, linnmich@comcast.net, for Targacept
Web site: http://www.targacept.com/
